Several other research analysts also recently weighed in on the stock. Cantor Fitzgerald set a $40.00 target price on shares of ProQR Therapeutics and gave the company a “buy” rating in a research note on Tuesday, January 29th. Chardan Capital restated a “buy” rating and issued a $25.00 target price (up from $21.00) on shares of ProQR Therapeutics in a research note on Tuesday, March 12th. HC Wainwright restated a “buy” rating and issued a $20.00 target price on shares of ProQR Therapeutics in a research note on Thursday, February 28th. ValuEngine downgraded shares of ProQR Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Saturday, April 13th. Finally, Zacks Investment Research downgraded shares of ProQR Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, March 19th. Two investment analysts have rated the stock with a sell rating and seven have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $28.67.
PRQR opened at $11.50 on Friday. The company has a quick ratio of 10.08, a current ratio of 10.08 and a debt-to-equity ratio of 0.14. ProQR Therapeutics has a 52-week low of $4.90 and a 52-week high of $24.00. The company has a market cap of $447.04 million, a price-to-earnings ratio of -8.91 and a beta of 0.50.
ProQR Therapeutics (NASDAQ:PRQR) last released its quarterly earnings data on Wednesday, February 27th. The biopharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.53) by $0.15. On average, research analysts predict that ProQR Therapeutics will post -1.65 earnings per share for the current fiscal year.
Several hedge funds have recently made changes to their positions in PRQR. BlackRock Inc. purchased a new position in shares of ProQR Therapeutics in the fourth quarter valued at $11,064,000. Hsbc Holdings PLC purchased a new position in shares of ProQR Therapeutics in the fourth quarter valued at $7,890,000. Nikko Asset Management Americas Inc. purchased a new position in shares of ProQR Therapeutics in the first quarter valued at $4,016,000. Federated Investors Inc. PA purchased a new position in shares of ProQR Therapeutics in the third quarter valued at $5,058,000. Finally, FMR LLC raised its holdings in ProQR Therapeutics by 27.8% in the fourth quarter. FMR LLC now owns 1,081,366 shares of the biopharmaceutical company’s stock valued at $17,064,000 after acquiring an additional 235,053 shares in the last quarter. Institutional investors and hedge funds own 60.19% of the company’s stock.
About ProQR Therapeutics
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. Its lead product candidates include eluforsen, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber's congenital amaurosis; QR-313, a dermatology candidate for the treatment of epidermolysis bullosa; and QR-421a and QR-411 to treat type 2A Usher syndrome.
Read More: Why do companies pay special dividends?
Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.